Find a Clinical Trial | Rutgers Cancer Institute of New Jersey

Print this page

Phase 1/1b Study of AKT Inhibitor Ipatasertib with Chemoradiation for Locally Advanced Head and Neck Cancer.
Protocol: 032204

Applicable Disease Sites: Larynx
Lip, Oral Cavity and Pharynx
A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib.
Protocol: 032207
Principal Investigator:
Applicable Disease Sites: Lung
A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-Naive Subjects with Advanced or Metastatic PD-L1 High [TPS>50%J Non-Small Cell Lung Cancer without Actionable Genomic Alterations (Tropion-Lung08) - Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-Line Treatment of Subjects with Advanced or Metastatic NSCLC without Actionable Genomic Alterations.
Protocol: 032211

Applicable Disease Sites: Lung
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer.
Protocol: 032212
Principal Investigator:
Applicable Disease Sites: Lung
A Phase 1/Ia Trial of AN0025 with Chemoradiation Therapy in Stage III NSCLC Patients.
Protocol: 032303
Principal Investigator:
Applicable Disease Sites: Lung
CTEP #10512: A Phase 2 Randomized Study of the BER Inhibitor TRC102 in Combination with Standard Pemetrexed-Platinum-Radiation in Stage III Non-Squamous Non-Small Cell Lung Cancer
Protocol: 032309
Principal Investigator:
Applicable Disease Sites: Lung
Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer.
Protocol: 032403

Applicable Disease Sites: Lip, Oral Cavity and Pharynx
INFORM Extended
Protocol: 042101
Principal Investigator:
Applicable Disease Sites: Breast
I-SPY 2 TRIAL: (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging And moLecular Analysis 2).
Protocol: 042102
Principal Investigator:
Applicable Disease Sites: Breast
A Phase II Study of U3-1402 in Patients with Metastatic Breast Cancer.
Protocol: 042103
Principal Investigator:
Applicable Disease Sites: Breast
A Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib.
Protocol: 042106
Principal Investigator:
Applicable Disease Sites: Breast
RADIANT Study: Phase Ib Study of Pre-op Radiation with Abemaciclib and Letrozole in Early Stage Breast Cancer.
Protocol: 042311
Principal Investigator:
Applicable Disease Sites: Breast
A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score less than or equal to 25 (OFSET).
Protocol: 042313
Principal Investigator:
Applicable Disease Sites: Breast
An Open-label, Multicenter, Phase 2 Dose Optimization and Expansion Study to Evaluate the Safety and Efficacy of BB-1701, an anti-human epidermal growth factor receptor 2 (anti-HER2) antibody-drug conjugate (ADC), in Previously Treated Subjects with HER2-positive or HER2-low Unresectable or Metastatic Breast Cancer
Protocol: 042314
Principal Investigator:
Applicable Disease Sites: Breast
A012103: OptimICE-PCR: De-Escalation of Therapy in Early-Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
Protocol: 042405
Principal Investigator:
Applicable Disease Sites: Breast
A Multicenter, Open Label, Phase III Extension Trial to Study the Long-Term Safety and Efficacy in Participants with Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial.
Protocol: 051804
Principal Investigator:
Applicable Disease Sites: Any Site